Patents Assigned to Leuven Research and Development
-
Patent number: 11524637Abstract: A vibration reduction device having an acoustic meta structure mounted to a vehicle body and configured to block a structure-borne noise transmitted through the vehicle body may include a plurality of unit structures arranged at a predetermined interval therebetween, wherein each of the unit structures includes frame mounted to the vehicle body and configured to separate a predetermined space into a predetermined number of separate sections formed by walls of the frame; and a vibrator formed at a corner portion of each of the separate sections and each of which has a natural frequency to block a vibration transmitted from the vehicle body through the frame.Type: GrantFiled: October 25, 2019Date of Patent: December 13, 2022Assignees: Hyundai Motor Company, Kia Motors Gorporation, Katholieke Universiteit Leuven of KU Leuven Research & DevelopmentInventors: Kyoung Jin Chang, Claus Claeys, Wim Desmet, Bert Pluymers, Elke Deckers, Lucas Van Belle, Noé Geraldo Rocha De Melo Filho
-
Patent number: 11174497Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. Preferably, the alcohol is ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.Type: GrantFiled: September 2, 2016Date of Patent: November 16, 2021Assignees: VIB VZW, K.U. Leuven Research & DevelopmentInventors: Kevin Verstrepen, Yudi Yang, Veerle Saels, Karin Voordeckers, Beatriz Herrera
-
Publication number: 20210128648Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.Type: ApplicationFiled: March 23, 2018Publication date: May 6, 2021Applicants: KU Leuven Research & Development, Universiteit AntwerpenInventors: Camille Allonsius, Ilke De Boeck, Stijn Wittouck, Sander Wuyts, Sarah Lebeer, Peter Hellings
-
Publication number: 20200180523Abstract: A vibration reduction device having an acoustic meta structure mounted to a vehicle body and configured to block a structure-borne noise transmitted through the vehicle body may include a plurality of unit structures arranged at a predetermined interval therebetween, wherein each of the unit structures includes frame mounted to the vehicle body and configured to separate a predetermined space into a predetermined number of separate sections formed by walls of the frame; and a vibrator formed at a corner portion of each of the separate sections and each of which has a natural frequency to block a vibration transmitted from the vehicle body through the frame.Type: ApplicationFiled: October 25, 2019Publication date: June 11, 2020Applicants: Hyundai Motor Company, Kia Motors Gorporation, Katholieke Universiteit Leuven of KU Leuven Research & DevelopmentInventors: Kyoung Jin CHANG, Claus Claeys, Wim Desmet, Bert Pluymers, Elke Deckers, Lucas Van Belle, Noé Geraldo Rocha De Melo Filho
-
Patent number: 10407623Abstract: The disclosure describes a one-step liquid biphasic catalytic process for converting a carbohydrate-containing feedstock, preferably lignocellulose, to light naphtha (e.g., hexane, pentane, methyl cyclopentane, cyclohexane, etc.) in the presence of an acidic reactive aqueous phase and a redox catalyst in the organic extracting/reaction phase. The process provides a cost-effective route for producing light-naphtha components, in presence or not of deoxygenates. The light naphtha components are useful as feedstock for steam and catalytic cracking to produce value-added platform molecules like ethylene and propylene, as precursor for the synthesis of bioaromatics like benzene and as gasoline fuel feedstock, and as fuel additives (e.g., the concomitantly formed oxygenates) to improve the biological origin of carbon in the fuel.Type: GrantFiled: May 12, 2015Date of Patent: September 10, 2019Assignee: Katholieke Universiteit Leuven, K.U. Leuven Research & DevelopmentInventors: Michiel Julien Dusselier, Beau Op De Beeck, Bert Frans Sels
-
Publication number: 20180312878Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. The alcohol may be, e.g., ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.Type: ApplicationFiled: September 2, 2016Publication date: November 1, 2018Applicants: VIB VZW, K.U. Leuven Research & DevelopmentInventors: Kevin Verstrepen, Yudi Yang, Veerle Saels, Karin Voordeckers, Beatriz Herrera
-
Patent number: 10087209Abstract: The present invention relates to novel pro-drugs of L-2?-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester pro-drugs. The invention also relates to a process for preparing these novel prodrugs of nucleoside phosphonates. The invention also relates to the use of these novel phosphonate-modified nucleosides to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the HBV family.Type: GrantFiled: April 27, 2016Date of Patent: October 2, 2018Assignee: KU LEUVEN RESEARCH & DEVELOPMENTInventors: Piet Herdewijn, Steven De Jonghe, Shrivinas Dumbre, Chao Liu
-
Publication number: 20180105552Abstract: The present invention relates to novel pro-drugs of L-2?-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester pro-drugs. The invention also relates to a process for preparing these novel prodrugs of nucleoside phosphonates. The invention also relates to the use of these novel phosphonate-modified nucleosides to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the HBV family.Type: ApplicationFiled: April 27, 2016Publication date: April 19, 2018Applicant: KU LEUVEN RESEARCH & DEVELOPMENTInventors: Piet HERDEWIJN, Steven DE JONGHE, Shrivinas DUMBRE, Chao LIU
-
Patent number: 9522932Abstract: The invention is directed to a process for the preparation of substituted threonolactone and substituted threose compounds which are intermediates in the synthesis of phosphonate nucleosides being useful antiviral agents.Type: GrantFiled: September 28, 2015Date of Patent: December 20, 2016Assignee: K.U. Leuven Research & DevelopmentInventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
-
Patent number: 9427447Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.Type: GrantFiled: September 10, 2014Date of Patent: August 30, 2016Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and DevelopmentInventors: Christopher McGuigan, Jan Balzarini, Marco Migliore
-
Patent number: 9249177Abstract: The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base.Type: GrantFiled: June 27, 2014Date of Patent: February 2, 2016Assignee: K.U. Leuven Research & DevelopmentInventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
-
Patent number: 9242983Abstract: Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), wherein the dashed lines, X, Y and R1 through R5 are as defined in the specification. The compounds are useful in the prophylaxis or treatment of viral infections.Type: GrantFiled: April 8, 2014Date of Patent: January 26, 2016Assignees: K.U. Leuven Research & DevelopmentInventors: Steven S. Bondy, David A. Oare, Gerhard Puerstinger
-
Patent number: 9155514Abstract: Reconstruction in positron emission tomography is performed with partially known attenuation. A PET-CT scanner is used to generate a PET image with time of flight emission information. To limit x-ray dose while providing increased sensitivity at the ends of the CT volume in the PET image, attenuation coefficients for oblique LORs passing outside the CT volume are determined from the time of flight emission information. The attenuation coefficients for LORs within the CT volume are derived from the CT data. An objective function may be maximized for the emission distribution without reconstructing the attenuation distribution.Type: GrantFiled: July 28, 2014Date of Patent: October 13, 2015Assignees: Siemens Medical Solutions USA, Inc., Katholieke Universiteit Leuven, Leuven Research & Development, Vrije Universiteit BrusselInventors: Vladimir Y Panin, Michel Defrise, Johan Nuyts
-
Patent number: 8884011Abstract: This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R1-R3 are as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and their use for the preparation of a medication for testing and/or preventing a viral infection in a patient. The invention also provides methods for making these compounds. In particular, the invention provides an H-phosphinate precursor intermediate of formula (II) wherein B is a purine or pyrimidine base as defined herein and R1 is selected from the group comprising a hydrogen atom, and a methyl, ethyl, hydroxymethyl, hydroxyethyl and C1-6haloalkyl group.Type: GrantFiled: November 8, 2007Date of Patent: November 11, 2014Assignees: Centre National de la Recherche Scientifique-CNRS, Universite d'Aix-Marseille, K.U. Leuven Research & DevelopmentInventors: Bruno Canard, Karine Alvarez, Karine Barral, Jean-Louis Romette, Johan Neyts, Jan Balzarini
-
Patent number: 8859512Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.Type: GrantFiled: November 30, 2012Date of Patent: October 14, 2014Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and DevelopmentInventors: Christopher McGuigan, Jan Balzarini, Marco Migliore
-
Patent number: 8809520Abstract: The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base.Type: GrantFiled: July 11, 2013Date of Patent: August 19, 2014Assignee: K.U. Leuven Research & DevelopmentInventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
-
Patent number: 8795806Abstract: A half closed thermoplastic folded honeycomb structure is described which is produced from a continuous web of material by plastic deformation perpendicular to the plane of the material to thereby form half-hexagonal cell walls and small connecting areas. By folding in the direction of conveyance the cell walls meet to thereby form the honeycomb structure.Type: GrantFiled: November 21, 2005Date of Patent: August 5, 2014Assignees: K.U. Leuven Research & Development, Jochen PflugInventors: Jochen Pflug, Ignace Verpoest
-
Patent number: 8790697Abstract: The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range of 0.4 to 2.0 nm.Type: GrantFiled: September 9, 2005Date of Patent: July 29, 2014Assignee: K.U. Leuven Research & DevelopmentInventors: Johan Martens, Guy Van Den Mooter, Jan Van Humbeeck, Caroline Aerts, Randy Mellaerts
-
Patent number: 8779141Abstract: The present invention relates to imidazo[4,5-c]pyridine compounds and pharmaceutical compositions for the treatment or prevention of viral infections, wherein the imidazo[4,5-c]pyridine compounds have the formula:Type: GrantFiled: May 19, 2009Date of Patent: July 15, 2014Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development, Gerhard PuerstingerInventors: Johan Neyts, Gerhard Pürstinger, Erik De Clercq
-
Patent number: 8722677Abstract: Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), wherein the dashed lines, X, Y and R1 through R5 are as defined in the specification. The compounds are useful in the prophylaxis or treatment of viral infections.Type: GrantFiled: June 22, 2012Date of Patent: May 13, 2014Assignees: Gilead Sciences, Inc., K.U. Leuven Research & DevelopmentInventors: Steven S. Bondy, David A. Oare, Gerhard Puerstinger